Lifemd Inc Stock Price, News & Analysis

LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced a quarterly cash dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend payment of $0.5546875 per share will be distributed on April 15, 2025, to shareholders of record as of April 4, 2025.

LifeMD (NASDAQ: LFMD) reported strong Q4 2024 financial results with consolidated revenues increasing 43% year-over-year to $64.3 million, driven by a 60% growth in telehealth revenue. The company achieved record quarterly adjusted EBITDA of $9.0 million, up 78% year-over-year.

Key highlights include telehealth adjusted EBITDA increasing 396% to $5.9 million, telehealth active subscribers growing 27% to 275,000, and WorkSimpli subscribers rising 3% to 164,000. The company ended 2024 with over $35 million in cash and improved full-year cash flow from operations by 99% to $17.5 million.

For 2025, LifeMD provided guidance of $265-275 million in consolidated revenue and $30-32 million in consolidated adjusted EBITDA. The company plans to launch Medicare services on April 1 and is preparing to introduce virtual-first behavioral health and women's health specialty offerings later in the year.

LifeMD (Nasdaq: LFMD) announced integration with LillyDirect's pharmacy provider Gifthealth to offer streamlined access to Zepbound® (tirzepatide), Lilly's FDA-approved prescription obesity treatment. The integration enables eligible patients to access single-dose vials at reduced self-pay prices with direct shipment.

Zepbound is the first dual GLP-1/GIP obesity medication approved by FDA. The integration complements LifeMD's insurance-sponsored pharmacy programs, where approval rates for branded GLP-1 therapies are increasing. The company's weight management program has reached approximately 75,000 active patient subscribers as of February 2025.

Through LillyDirect's self-pay pharmacy channel, Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg dose vials. Lilly has reduced prices for 2.5 mg and 5 mg vials and launched new 7.5 mg and 10 mg vial options.

LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its upcoming participation in the KeyBanc Capital Markets Healthcare Forum. The event will be held virtually from March 18-19, 2025.

The company's management team is scheduled to engage in a fireside chat on Tuesday, March 18th at 11:15 a.m. Eastern time. Additionally, they will conduct one-on-one meetings throughout the duration of the conference.

LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, has announced it will report its financial results for the fourth quarter and full year of 2024 on March 10, 2025.

The company will release its three and 12-month financial results ended December 31, 2024, after the close of U.S. financial markets on the scheduled date. Following the release, LifeMD will host a conference call beginning at 4:30 p.m. Eastern time to discuss the results.

LifeMD (NASDAQ: LFMD) announced its expansion into the behavioral health market, adding teletherapy, psychiatry, and medication management services for mental health conditions. The company appointed Julian Cohen as Senior Vice President of Behavioral Health & Clinical Operations to lead this initiative.

Cohen brings over 30 years of healthcare industry experience, including executive roles at UpLift, Hims, Teladoc Behavioral Health, and as co-founder/CEO of Breakthrough Behavioral. The expansion aims to address the significant mental health treatment gap, as only 50.6% of the 59.3 million U.S. adults with mental illness received treatment in 2022.

LifeMD plans to improve accessibility through expanded insurance coverage across commercial and government payers. The company particularly notes the high prevalence of mental health conditions among young adults (36.2%) and the correlation between obesity and psychiatric illness (20-60% of obese individuals).

Medifast (NYSE: MED) reported Q4 2024 financial results with revenue of $119.0 million, down 37.7% from Q4 2023, primarily due to a 34.1% decrease in active OPTAVIA coaches to 27,100. Revenue per active coach declined 5.5% to $4,391.

Q4 net income was $0.8 million ($0.07 per share), compared to $6.0 million ($0.55 per share) in Q4 2023. Full-year 2024 revenue decreased 43.8% to $602.5 million, with net income of $2.1 million ($0.19 per share).

The company maintains a strong balance sheet with $162.3 million in cash and investments with no debt. For Q1 2025, Medifast expects revenue between $100-120 million and EPS ranging from a loss of $0.50 to $0.00 per share.

Medifast (NYSE: MED), the health and wellness company behind the OPTAVIA® lifestyle solution, has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 18, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be broadcast live on Medifast's Investor Relations website and will remain archived through May 18, 2025. Telephone participants can dial (201) 389-0879 to join, with a playback available from 8:30 p.m. ET through February 25, 2025, accessible at (412) 317-6671 with access code 13751326.

LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The conference is scheduled for February 11-12, 2025, and will take place at the Cliff Lodge in Snowbird, Utah. The company's management team will be conducting one-on-one meetings throughout the duration of the conference.